| Autor: |
Jennifer L Leddon, Chun-Yu Chen, Mark A Currier, Pin-Yi Wang, Francesca A Jung, Nicholas L Denton, Kevin M Cripe, Kellie B Haworth, Michael A Arnold, Amy C Gross, Timothy D Eubank, William F Goins, Joseph C Glorioso, Justus B Cohen, Paola Grandi, David A Hildeman, Timothy P Cripe |
| Jazyk: |
angličtina |
| Rok vydání: |
2014 |
| Předmět: |
|
| Zdroj: |
Molecular Therapy: Oncolytics, Vol 1, Iss C (2014) |
| Druh dokumentu: |
article |
| ISSN: |
2372-7705 |
| DOI: |
10.1038/mto.2014.10 |
| Popis: |
Multiple studies have indicated that in addition to direct oncolysis, virotherapy promotes an antitumor cytotoxic T cell response important for efficacy. To study this phenomenon further, we tested three syngeneic murine sarcoma models that displayed varied degrees of permissiveness to oncolytic herpes simplex virus replication and cytotoxicity in vitro, with the most permissive being comparable to some human sarcoma tumor lines. The in vivo antitumor effect ranged from no or modest response to complete tumor regression and protection from tumor rechallenge. The in vitro permissiveness to viral oncolysis was not predictive of the in vivo antitumor effect, as all three tumors showed intact interferon signaling and minimal permissiveness to virus in vivo. Tumor shrinkage was T-cell mediated with a tumor-specific antigen response required for maximal antitumor activity. Further analysis of the innate and adaptive immune microenvironment revealed potential correlates of susceptibility and resistance, including favorable and unfavorable cytokine profiles, differential composition of intratumoral myeloid cells, and baseline differences in tumor cell immunogenicity and tumor-infiltrating T-cell subsets. It is likely that a more complete understanding of the interplay between the immunologic immune microenvironment and virus infection will be necessary to fully leverage the antitumor effects of this therapeutic platform. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
